Short Interest in Genmab A/S (NASDAQ:GMAB) Expands By 9.6%

Genmab A/S (NASDAQ:GMAB) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 2,630,000 shares, a growth of 9.6% from the March 31st total of 2,400,000 shares. Based on an average trading volume of 575,800 shares, the short-interest ratio is currently 4.6 days. Currently, 0.4% of the shares of the company are sold short.

Institutional Trading of Genmab A/S

A number of hedge funds have recently bought and sold shares of GMAB. Headlands Technologies LLC purchased a new stake in Genmab A/S during the third quarter valued at about $27,000. Pinnacle Bancorp Inc. increased its holdings in shares of Genmab A/S by 315.8% in the 4th quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company’s stock valued at $27,000 after purchasing an additional 638 shares during the period. GAMMA Investing LLC increased its holdings in shares of Genmab A/S by 194.0% in the 1st quarter. GAMMA Investing LLC now owns 1,135 shares of the company’s stock valued at $34,000 after purchasing an additional 749 shares during the period. NBC Securities Inc. acquired a new position in shares of Genmab A/S in the 3rd quarter valued at about $37,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Genmab A/S by 86.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,075 shares of the company’s stock valued at $38,000 after purchasing an additional 498 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently commented on GMAB. Citigroup lowered shares of Genmab A/S from a “neutral” rating to a “sell” rating in a research report on Monday, January 22nd. Morgan Stanley reaffirmed an “underweight” rating on shares of Genmab A/S in a report on Tuesday, March 26th. BMO Capital Markets raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $46.00 to $48.00 in a report on Friday, February 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a report on Tuesday. Finally, Truist Financial reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a report on Tuesday, March 26th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $48.50.

Genmab A/S Trading Up 3.8 %

Shares of NASDAQ GMAB opened at $28.75 on Thursday. Genmab A/S has a twelve month low of $26.32 and a twelve month high of $42.72. The company has a market capitalization of $19.01 billion, a price-to-earnings ratio of 29.95, a PEG ratio of 2.05 and a beta of 0.99. The firm has a 50-day moving average of $29.41 and a two-hundred day moving average of $29.93.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, February 14th. The company reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.02. Genmab A/S had a net margin of 26.50% and a return on equity of 18.06%. The company had revenue of $675.29 million during the quarter, compared to the consensus estimate of $678.14 million. As a group, research analysts predict that Genmab A/S will post 1.06 earnings per share for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.